Skip to main content
TipRanks
Go Ultimate75% OFF

Feedback (FDBK) AI Stock Analysis

3 Followers
GB:FDBK

Feedback

(LSE:FDBK)

Select Model
Rating:37Underperform
Price Target:GBX 3.50▼(-1.41% Downside)
Action:downgraded
Date:11/10/26

The overall score is at the minimum of 37, reflecting a company in severe distress across all evaluated dimensions. The most significant factor is the dire financial performance, marked by collapsing revenue, margins, and accelerating cash burn that threatens the company's survival. This is compounded by a deeply bearish technical trend with the stock price below all key moving averages and extremely weak momentum. The negative P/E ratio confirms a lack of earnings power, providing no valuation support. The debt-free balance sheet is the only mitigating factor, but it is being rapidly eroded by ongoing losses.

Positive Factors
Debt-free balance sheetThe absence of reported debt limits interest and refinancing burdens, preserving financial flexibility while the company develops its healthcare software. This gives management more room to allocate resources toward operations and product development without debt servicing further increasing cash pressure.
Negative Factors
Shrinking revenueConsecutive revenue declines indicate that the current business has not yet established a dependable growth trajectory. Shrinking scale makes it harder to absorb fixed operating costs, limits reinvestment capacity, and increases the challenge of converting the platform’s healthcare use case into sustainable expansion.

Feedback (FDBK) vs. iShares MSCI United Kingdom ETF (EWC)

-75%-50%-25%0%25%50%75%100%GB:FDBK-57.49%EWC+18.88%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 1.56M
Dividend Yield
―
Average Volume (3M)
95.21K
Price to Earnings (P/E)
-0.4
Beta (1Y)
0.65
Revenue Growth
-11.91%
EPS Growth
69.57%
Country
UK
Employees
26
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

Feedback Business Overview & Revenue Model

Company Description

Feedback plc is a medical technology company, headquartered in London, UK, and established in 1958, that supplies specialized software and systems to individuals and organizations working within the medical imaging sector. Their product portfolio inc...

Feedback Financial Statement Overview

Summary

Financial health is critically weak. Revenue is in steep decline, gross margins have collapsed from over 90% to 45.6%, and the net loss margin is -447%. The only positive is a debt-free balance sheet, but equity is eroding rapidly and cash burn is severe, with negative free cash flow threatening the company's viability.

Income Statement

18Very Negative

Balance Sheet

55Neutral

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMMay 2025May 2024May 2023May 2022May 2021
Income Statement
Total Revenue780.14K780.14K885.62K1.18M1.02M588.58K
Gross Profit355.77K355.77K778.65K1.10M131.39K-63.68K
EBITDA-3.18M-3.13M-3.06M-2.73M-2.61M-1.96M
Net Income-3.49M-3.49M-7.32M-3.30M-2.92M-2.12M
Balance Sheet
Total Assets3.42M3.42M6.75M8.34M11.72M14.30M
Cash, Cash Equivalents and Short-Term Investments2.73M2.73M5.95M3.88M7.32M10.31M
Total Debt000000
Total Liabilities663.97K663.97K589.02K694.18K855.45K594.13K
Stockholders Equity2.75M2.75M6.16M7.64M10.87M13.71M
Cash Flow
Free Cash Flow-2.79M-2.79M-2.83M-2.14M-2.99M-2.41M
Operating Cash Flow-2.79M-2.79M-2.82M-2.22M-1.74M-1.25M
Investing Cash Flow-429.54K-429.54K-716.00K-1.22M-1.24M-1.15M
Financing Cash Flow005.61M0-83010.49M

Feedback Technical Analysis

Technical Analysis SentimentNegative
Last Price3.55

Price Trends

50DMA6.03Negative
100DMA6.25Negative
200DMA8.49Negative

Market Momentum

MACD-0.75Positive
RSI14.06Positive
STOCH1.33Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:FDBK, the sentiment is Negative. The current price of 3.55 is below the 20-day moving average (MA) of 5.28, below the 50-day MA of 6.03, and below the 200-day MA of 8.49, indicating a bearish trend. The MACD of -0.75 indicates Positive momentum. The RSI at 14.06 is Positive, neither overbought nor oversold. The STOCH value of 1.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:FDBK.

Feedback Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:FDBK against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:KOOGB:KOO81OutperformGBP 67.37M11.2217.74%―-6.51%108.62%
GB:IXIGB:IXI55NeutralGBP 27.92M-6.50-16.18%―13.04%15.88%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:GDRGB:GDR49NeutralGBP 14.45M-0.82-1044.57%―65.60%74.84%
GB:COGGB:COG41NeutralGBP 15.65M-9.63-54.17%―11.86%23.81%
GB:OBDGB:OBD40UnderperformGBP 15.46M-0.29-451.74%―33.37%86.41%
GB:FDBKGB:FDBK37UnderperformGBP 1.56M-0.45-96.66%―-11.91%69.57%

* Healthcare Sector Average

Performance Comparison

-50%0%50%GB:FDBKGB:COGGB:GDRGB:IXIGB:OBDGB:KOODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:FDBK and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:FDBKFeedback plc3.55-5.05-58.72%
GB:COGCambridge Cognition Holdings29.00-4.00-12.12%
GB:GDRGenedrive plc0.90-0.04-4.56%
GB:IXIIXICO plc12.751.7515.91%
GB:OBDOxford BioDynamics0.12-0.17-58.93%
GB:KOOKooth Plc181.0053.5041.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026